Firms owed $1.7m by OneLife Labs

OneLife Labs owes more than A$1.7 million to creditors, including $365,000 to Colombian producer Clever Leaves, as potential buyers continue to explore the acquisition of its manufacturing facility.

Health House parent hits financial wall as Melodiol enters administration

Health House parent Melodiol Global Health has entered voluntary administration, the third medicinal cannabis company to hit the financial wall in the space of six weeks.

Epsilon sets ‘roadmap’ but issues remain as firm seeks ASX return

Epsilon Healthcare has “re-established its foundation” and has a “clear roadmap for sustainable profitability”, its chairman has said.

Homepage

An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient-specific and evidence-based information to support health professionals in prescribing and patient care decisions. This study aimed to describe real-world data collected by CMAS.

A sub-set of de-identified, patient-specific enquiries collected between January 2021 and June 2022 (n = 123/567; 21.7%) were analyzed using R version 4.2.1. Diagnosis, indication, and comorbidities were coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology.

Most patient-specific enquiries from medical practitioners were from general practitioners (n = 103/123; 83.7%). Female (n = 53/123; 43.1%) and male (n = 59/123; 48.0%) patients were similarly represented. Sex was not specified for 8.9% (n = 11/123) of patients. The mean age of patients was 52.1 years (range <10-90). The most common three diagnoses were osteoarthritis, anxiety, and chronic pain. Indications that were most frequently reported included chronic pain, anxiety, back pain, non-neuropathic pain, and insomnia. Comedications were most commonly non-opioid and opioid analgesics and antidepressants. Most practitioners were considering prescribing a cannabidiol (CBD) product for their patient. Cannabinoid composition selection guidance provided by CMAS was predominantly (delta-9-tetrahydrocannabinol) THC:CBD ~1:1, followed by CBD-only products. CMAS was contacted by health professionals regarding the management of potential adverse events for five patients.

The findings of this study shed light on the information medical practitioners were seeking to inform their clinical decision-making about medical cannabis and can inform the development of clinical guidance resources.

© 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.

Hi I noticed you had a post about Zenith clinics I recently had a run in with them as I was seeking medication.

They are a scam they take your money which was $29 for the initial consult which they say they will return it’s just a pending holding fee for the consult.

A “so called doctor gives you a call on zoom they prescribe you”.

After two weeks nothing happened I called several times and got the same person with a south African accent they keep on telling me they are waiting for TGA approval this goes on and on they say it sometimes takes a long time.

I was fed up so I called ******* scripts got a free appointment the next day she prescribed me and the TGA approval only took 48hrs and I have the product now already.

I am yet to hear back from Zenith clinic. It’s not the money as it was only $29 but it’s the deception they must be doing this to a lot of people who really need medicine. I wanted to send this as people need to be warned so they are to right decision.